MT Newswires
RBC Raises Price Target on Fulcrum Therapeutics to $10 From $7, Keeps Sector Perform, Speculative Risk
📊
AI Sentiment
Positive
6/10
Fulcrum Therapeutics Inc. News
Latest updates and market news for FULC
4 news
Dec 4 - Dec 10, 2025
Page 1
MT Newswires
Fulcrum Therapeutics Reports Positive Initial Results from Trial of Pociredir in Sickle Cell Disease; Shares Surge Pre-Bell
📊
AI Sentiment
Positive
7/10
GlobeNewswire
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
📊
AI Sentiment
Positive
6/10
Share this news page